ADVI Health is a global team of technical experts, data scientists, clinicians, product innovators, and payer Advisors. ADVI assists clients through commercialization, with the strategy, analytics, and operational know-how to enable it — and a level of collaboration unmatched in the industry.
Our history of successful growth for over a decade is directly attributable to our commitment to our clients — many of whom worked with our team long before ADVI existed, most for over 15 years — our interest in politics, our passion for policy as a driver of access and reimbursement, and our speed in addressing the thorniest business issues. We bring our specific subject-matter expertise, an encyclopedic knowledge of rules and regulations, and a long history of success. We combine the advice, action, and tools of traditional consulting with the rigor and vision of experienced corporate strategists. Our unique datasets and targeted advocacy advance innovation for leading cell, biologic, drug, and gene therapy, device and supply, and molecular-diagnostics manufacturers, digital-therapy companies, trade associations, provider and patient advocacy groups and organizations, and cancer providers.
ADVI's approach is centered on our Solution areas:
- State and Federal Policy
- Market Access
- Financial Due Diligence
- Coding and Reimbursement
- Strategic Analytics and Value Economics
These are supported by two dedicated service lines: advisory services and insights. By collaborating, we deliver results for emerging biotech firms and established pharmaceutical companies, MedTech (devices, digital therapeutics, and AI), precision medicine, provider groups, trade associations, private equity, and venture capital. Our cross-disciplinary Solutions teams and our industry-leading team of former payers, government officials, and brand and market strategists support clients throughout the product lifecycle from bench to bedside, molecule to market — in corporate development, pre-commercial planning, pre- and peri-launch, and through commercial execution.
In December 2022, ADVI decided to bring on a strategic partner, Sheridan Capital Partners (SCP), a Chicago-based healthcare-focused private equity firm. The collaboration with SCP enables ADVI to accelerate our growth by investing in key areas of our business to bring unique data-informed solutions to the market while expanding our core products and services. We are focused on expanding in the following areas: pricing; contracting; and go-to-market capabilities for our life sciences customer base; a deeper focus on data assets; health economics and outcomes research; and due diligence for capital markets. This partnership accelerates our ability to help clients with data analytics by locking in unique and proprietary datasets, products, and proven business improvement methods.
We advance patient access, accelerate time to reimbursement, and provide winning business and strategic advice to life sciences companies and healthcare innovators, established companies, those that provide care on their behalf, and those that fund them.
August 23, 2024 — ADVI Health is pleased to announce the acquisition of Partnership for Health Analytic Research (PHAR), a global health technology assessment (HTA) and health economics and outcomes research (HEOR) consultancy, known for providing high-impact, data-driven insights to some of the largest biopharmaceutical sponsors and clients.
